This article is more than 5 years old. Information may no longer be current.

VIDEO: Concepts for targeting estrogen receptor function have, will continue to evolve

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Gianni Bonadonna Breast Cancer Award lecture at the ASCO Annual Meeting by C. Kent Osborne, MD, of Baylor College of Medicine, provided an “excellent overview and history of targeting the estrogen receptor” for the treatment of breast cancer, according to Douglas Yee, MD, of the Masonic Cancer Center at the University of Minnesota.

Yee, who is also a HemOnc Today Editorial Board member, describes Osborne’s lecture, which reviewed how estrogen receptor function has been targeted and how therapies like tamoxifen, fulvestrant and aromatase inhibitors impact this process. The lecture concluded “with the idea that there’s still a lot to learn,” according to Yee.

Current studies that are investigating new ways to treat this type of cancer “should lead to better outcomes for women with the largest subset of breast cancer – those that are ER-positive,” he said.